SCHEMBL22010522

SCHEMBL22010522

COC(=O)C(Cc1ccccc1)CS(=O)(Cl)=N[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA14 Q9ULX7 2/20 0.38
▸ CA2 P00918 1/20 0.38
▸ FOLH1 Q04609 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ MIF P14174 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ ITGB7 P26010 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ BIRC2 Q13490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25829682 0.80 KMT2A (0.46) POLBKMT2AMEN1CA12CA7
SCHEMBL22010524 0.78 KMT2A (0.46) POLBKMT2AMEN1CA12CA7
SCHEMBL7332197 0.77 KMT2A (0.50) POLBKMT2AMEN1CA12CA7
SCHEMBL7269972 0.75 POLB (0.48) POLBKMT2AMEN1CA12CA7
SCHEMBL24162576 0.75 KCNN4 (0.35) KMT2AMEN1HSD17B10
SCHEMBL22010526 0.75 POLB (0.44) POLBKMT2AMEN1CA12CA7
SCHEMBL21962937 0.73 KMT2A (0.51) POLBKMT2AMEN1CA12CA7
SCHEMBL7335528 0.72 KMT2A (0.50) POLBKMT2AMEN1CA12CA7
SCHEMBL21962922 0.72 KMT2A (0.57) POLBKMT2AMEN1CA12CA7
SCHEMBL4610145 0.71 ITGA4 (0.44) POLBKMT2AMEN1CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102100-A9 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2022-01-06 — — WO disclosed
WO-2020102100-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 — — WO disclosed
Send feedback